Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • National Cancer Institute is funding research on using programmable synthetic messenger RNA to treat two types of s… https://t.co/kYyOAY6MOf
    about 10 hours ago
  • New post on Science and Enterprise: NIH Funds Programmable mRNA to Treat Cancer https://t.co/DKptaY956d #Science #Business
    about 10 hours ago
  • Attn @ArcticFisheries .. Why Migraine Sufferers May Want to Eat More Fish https://t.co/3AaUvjuNqT
    about 14 hours ago
  • Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and ther… https://t.co/iJUJA00PmY
    about 1 day ago
  • New post on Science and Enterprise: Sanofi Acquires mRNA Developer in $3.2B Deal https://t.co/lRVt9pv3bq #Science #Business
    about 1 day ago

Please share Science & Enterprise

Universities License Regenerative Membrane Technology

Right Human Carpa lBones (Wikimedia Commons)

(Wikimedia Commons)

The technology transfer offices at Hebrew University of Jerusalem and Hadassah University Medical Center in Israel, say they have licensed technology for regenerative membrane implants developed at their institutions. RegeneCure, the licensee — also in Jerusalem — will further develop and commercialize the technology for bone tissue engineering in trauma, spine, and reconstructive cranial and facial orthopedics.

The membrane implant has a microporous surface that encourages the bone’s mesenchymal stem cells (MSCs) to adhere to the injured site through a signaling mechanism known as chemotaxis. The membrane helps the MSCs multiply and differentiate into bone tissue in the area of need. The membrane implant also serves as a barrier preventing scar tissue to infiltrate into the fracture and slow down the regenerative healing process.

Current methods that facilitate bone regeneration and healing of non-union fractures are based on autografts, bone transplantation from the patient’s body, or else by adding bone graft substitutes that help fill the fractured gap. On the other hand, RegeneCure says its MSC scaffolding method improves natural bone healing because of the implant’s ability to attract bone stem cells, enhance their proliferation, and form new bone tissue.

Under the terms of the agreement, RegeneCure receives the worldwide exclusive right to develop and commercialize the technology. In return, Yissum and Hadasit, the technology transfer units at Hebrew University of Jerusalem and Hadassah University Medical Center, will receive license fees, milestones, and royalty payments from future sales of RegeneCure’s products developed from the technology.

*     *     *

1 comment to Universities License Regenerative Membrane Technology